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In the published original article, Table 4, column "Frequency" contains some wrong terms.

The correct table is given here.Table 4Studies with gemcitabine and fluoropyrimidines in refractory mCRCStudyChemotherapyDose mg/m^2^/dFrequency*N*RR (%)Disease control (%)mPFSmOSNeutrop. G3/4 (%)Fillos \[17\]Gemcitabine750Day 1 every 7 days × 6263.834.82.711.3455-FU450Day 1 every 7 days × 6Pachon \[19\]Gemcitabine800--1,250Day 1, 15 every 21180703.79.905-FU (IC)200Every 21 daysBitossi \[13\]Gemcitabine1,000Day 1, 8, 15 every 283710.861.84.28.985-FU (IC)200Every 28 daysMadaje Wicz \[20\]Gemcitabine900Day 1 every 7 days × 62138NRNRNR115-FU450Day 1 every 7 days × 6Schilsky \[15\]Gemcitabine1,000Day 1, 8, 15 every 28219.614.4NRNR7.5Capecitabine1,66021 days every 28Fernandez \[21\]Gemcitabine900Day 1 every 1421NRNR49NRCapecitabine2,5007 days every 14Qiu \[18\]Gemcitabine1,000Day 1, 8 every 2112036.42.275.5717Capecitabine2,00014 days every 21Current studyGemcitabine1,000Day 1 every 141197452.876.530Capecitabine2,0007 days every 14*d* day, *RR* response rate, *mPFS* median progression-free survival, *mOS* median overall survival, *Neutrop* neutropenia

The online version of the original article can be found under doi:10.1007/s12094-014-1243-1.
